Table 1. Characteristics, treatment and outcome of Influenza A(H1N1)pdm09-infected CF patients.

Country	Inf A(H1N1)pdm09 infection in CF patients			Characteristics of CF patients infected with Inf A(H1N1)pdm09 (%)				Treatment (%)	Outcome (%)			Conclusion/Recommendation	Ref
	N 1	Age 2	Incidence * (%)	P. aerug.	Pancreatic	FEV1	Vacc	Oseltamivir	Hospital	ICU 4 or	CFR 5
				//	Insufficiency	pred 3		//	admission	ventilation
				B. cepacia				Antibiotics
				coinfection
Europe#	110	13	2.3*	n.r.	84	69	8.8	81/66	48	5.4	2.7	awareness,	[39]
								81//66
												infection control,
												vaccination campaign
Italy#	68	15	53**	48.5//8.8	89.7	53	13.2	82//68	69	1.5 ventilation	4.4	annual vaccination in	[41]
				48.5//8.8
										13.2 on oxygen		adult CF patients
Australia	11	22	4.4*	100//1	n.r.	66	n.av.	100//75	63	n.r.	n.r.	prompt	[42]
				100//1
												commencement of
												oseltamivir and
												antibiotic therapy
UK	13	22	4*	100//n.r.	n.r.	51.4	n.r.	100//100	69	0	n.r.	generally mild illness	[40]
					n.r.			100//100
												in CF,
												potentially more
												virulent pandemic in
												the future

¹ Number of Influenza A(H1N1)pdm09 positive CF patients.

² Mean age (years).

³ Mean of all CF patients studied.

⁴ Intensive care unit.

⁵ Case fatality rate.

^# multicenter surveys;

incidence of Inf A(H1N1)pdm09 infections in CF patients.

incidence of Inf A(H1N1)pdm09 infections relating to CF patients with influenza-like illness.

(ILI); n.r. – not reported; Vacc – Vaccination coverage; P. aerug. = Pseudomonas aeruginosa; B. cepacia = Burkholderia cepacia.